If you have been reading about DAC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
In addition to psychedelics being defined as controlled substances at the federal level, individual U.S. states, such as Alabama, may also make psychedelics controlled substances within their jurisdictions. Conversely, state-level and lower jurisdictions may alternatively legalize or decriminalize psychedelics, for instance Colorado and Oregon and individual cities like San Francisco. This can result in legal conflict and ambiguity at different levels of government, for example a given drug being illegal at the federal level but legal at the state level.
Depending on the manufacturing process, enantiopure forms can be more expensive to produce than stereochemical mixtures. Chiral preferences can also be found at a macroscopic level. Snail shells can be right-turning or left-turning helices, but one form or the other is strongly preferred in a given species. In the edible snail Helix pomatia, only one out of 20,000 is left-helical. The coiling of plants can have a preferred chirality and even the chewing motion of cows has a 10% excess in one direction.
Pin-point pupils may occur. Patient presenting with dilated pupils may still be experiencing an opioid overdose. Decreased heart rate Decreased body temperature Decreased breathing Altered level of consciousness. People may be unresponsive or unconscious. Pulmonary edema (fluid accumulation in the lungs) Shock Death
Sources: en.wikipedia.org
Some border zones, referred to as border vistas, are composed of legally mandated cleared space between two areas of foliage located at an international border intended to provide a clear demarcation line between two jurisdictions. Border vistas are most commonly found along undefended international boundary lines, where border security is not as much of a necessity and a built barrier is undesired, and are a treaty requirement for certain borders. An example of a border vista is a 6-metre (20-foot) cleared space around unguarded portions of the Canada–United States border. Similar clearings along the border line are provided for by many international treaties. For example, the 2006 border management treaty between Russia and China provides for a 15-metre (49-foot) cleared strip along the two nations' border. In 2024, Egypt announced that they are building a buffer zone on the Egypt-Gaza border.
pachynema Also pachytene stage. In meiosis, the third of five substages of prophase I, following zygonema and preceding diplonema. During pachynema, the synaptonemal complex facilitates crossing over between the synapsed homologous chromosomes, and the centrosomes begin to move apart from each other.
=== United Cup === Zverev has started his season every year since 2023 by participating in the United Cup. In 2023, Zverev and Team Germany were placed in Group C alongside the Czech Republic and the USA. Against the Czech Republic, he lost to Jiří Lehečka. The Czech Republic won the tie over Germany 3–2. Against the US, he lost to Taylor Fritz. The USA beat Germany 5–0. Germany failed to qualify for the knockout round and ended third in Group C. In 2024, Zverev returned to the United Cup in Sydney, Australia for the second consecutive year, leading Team Germany alongside Angelique Kerber. He won both of his singles matches in the round-robin stage, defeating Lorenzo Sonego of Italy and Adrian Mannarino of France both in three sets. He played both mixed doubles matches in both ties with Angelique Kerber, partnering for the first time since 2019, and won against Team Italy but not Team France. Despite this, Team Germany managed to qualify as the best runner-up team from all countries participating in Sydney, advancing to the quarterfinals against Greece. There, Zverev decisively won his singles match against Stefanos Tsitsipas and his mixed doubles match, partnering with doubles specialist Laura Siegemund, against Maria Sakkari and Petros Tsitsipas. In the semifinal tie against Australia, Zverev was defeated by Alex de Minaur in three sets, allowing the Australian to crack the top 10 after previously making top 10 wins against Taylor Fritz and Novak Djokovic earlier that week.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.